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Abstract
Background: Lower respiratory tract infections continue to contribute significantly to morbidity and mortality
across all age groups globally. In sub-Saharan Africa, many studies of community acquired pneumonia in adults
have focused on HIV-infected patients and little attention has been given to risk factors and etiologic agents in an
urban area with a more moderate HIV prevalence.
Methods: We prospectively enrolled 77 patients admitted to a 280 bed teaching hospital in Kenya with
radiographically confirmed community acquired pneumonia from May 2019 to March 2020. The patients were
followed for etiology and clinical outcomes. Viral PCR testing was performed using the FTD respiratory pathogen-21
multiplex kit on nasopharyngeal or lower respiratory samples. Additional microbiologic workup was performed as
determined by the treating physicians.
Results: A potential etiologic agent(s) was identified in 57% including 43% viral, 5% combined viral and bacterial,
5% bacterial and 4% Pneumocystis. The most common etiologic agent was Influenza A which was associated with
severe clinical disease. The most common underlying conditions were cardiovascular disease, diabetes and lung
disease, while HIV infection was identified in only 13% of patients. Critical care admission was required for 24, and
31% had acute kidney injury, sometimes in combination with acute respiratory distress or sepsis.
Conclusion: Viruses, especially influenza, were commonly found in patients with CAP. In contrast to other studies
from sub-Saharan Africa, the underlying conditions were similar to those reported in high resource areas and point
to the growing concern of the double burden of infectious and noncommunicable diseases.
Keywords: Pneumonia, Viral pneumonia, Community acquired pneumonia, Sub-Saharan Africa, Kenya, Influenza,
Tuberculosis, Pneumocystis jirovecii, Diabetes, HIV
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Background
According to the Global Burden of Diseases (GBD),
lower respiratory tract infections (LRIs) were reported
to have caused 2.7 to 2.8 million deaths per year
from 2005 to 2015 and close to half of these were
among adults [1]. Sub-Saharan Africa (SSA) is dispro-
portionately affected by a higher burden of lower re-
spiratory tract infections which affect a much younger
population when compared to the North American
and European cohorts [2].
Studies on viral etiology of community acquired pneu-
monia (CAP) among adults within the sub-Saharan Afri-
can region are scarce and where available, are often
combined with pediatric cohorts [3]. In addition, some
of the reports are from settings with very high HIV and
tuberculosis prevalence. The high prevalence of HIV-
associated comorbidities, lack of control cohorts and ab-
sence of standard definitions make it difficult to consist-
ently determine and define the overall burden of viral
lower respiratory disease or characterize disease by eti-
ology [3]. In contrast, Kenya had an estimated HIV
prevalence of 4.9% in 2017 (6.1% in Nairobi), which
places it above most countries in other continents but
substantially lower than many countries of sub-Saharan
Africa [4]. The prevalence of non-communicable dis-
eases (NCDs) such as obesity and diabetes mellitus has
been increasing in sub-Saharan Africa, creating new po-
tential risk factors for CAP. These conditions have been
associated with increased susceptibility to viral infections
especially with influenza among diabetic patients [5–7].
Having recognized this inimical synergy, some countries,
such as South Africa, have designed and rolled out spe-
cific health care guidelines for the management of CAP
among susceptible groups including those with diabetes
mellitus [8].
Before the onset of the COVID-19 pandemic, influenza
was the most common cause of severe life threatening
and vaccine preventable viral lower respiratory disease
among adults worldwide [9–12]. In addition, numerous
other viral pathogens are recognized as important causes
of lower respiratory tract infections (LRTI). Respiratory
syncytial virus (RSV) is second to Influenza as a cause of
LRTI and shows winter seasonality similar to influenza
in temperate climates [13–16]. Human metapneumo-
virus and human parainfluenza virus are within the same
family of viruses as RSV and cause influenza-like symp-
toms in high-risk populations such as the elderly and
the immunocompromised [17–20]. In addition, adenovi-
ruses [21] and rhinoviruses [11] are sometimes impli-
cated as causes of LRTI.
We have therefore investigated the roles of these viral
pathogens as causes of CAP in a setting with moderate
levels of HIV and a growing prevalence of diabetes,
hypertension and other NCDs.
Methods
Setting
The Aga Khan University hospital is a teaching hospital
in Nairobi with 280 beds that include 33 adult critical
care beds and over 20 medical specialties. The hospital
has been accredited by the Joint Commission Inter-
national since 2013 and the laboratory has been accre-
dited by SANAS since 2011 [22] and by the College of
American Pathologists since 2018.
Study design and definitions
We conducted a prospective observational study of inpa-
tients with community acquired pneumonia from May
1st, 2019 until March 13th, 2020. The enrollment was
planned for a complete year but was terminated in
March due to the COVID-19 pandemic. The first case in
Kenya was reported on March 13, 2020. This series
therefore represents the spectrum of pre-COVID-19
pneumonia.
Patients over 18 years of age admitted with suspected
community acquired pneumonia were approached for
enrollment if they had a new infiltrate on pulmonary im-
aging with compatible symptoms such as cough, fever,
breathlessness, and production of sputum. Patients were
excluded if they had a pulmonary infection within 6
weeks of presentation or chronic lung disorders judged
to be significant enough to compromise interpretation of
the diagnosis or outcome of pneumonia. Chest images
(chest radiograph or CT Scan) obtained within 72 h of
admission were used to identify changes consistent with
lower respiratory infection findings, including opacities,
effusions, consolidations, and other findings. For patients
where both radiograph and CT were done, analysis was
based on CT findings. All enrolled patients were
followed up for critical care admission within 30 days
and for discharge status (alive/dead) or death within 30
days.
Acute kidney injury (AKI) was defined using the
KDIGO criteria [23]. Sepsis was defined using the Sepsis
3 criteria [24] as life-threatening organ dysfunction
caused by a dysregulated host response to infection
using the Sequential Organ Failure Assessment (SOFA)
to identify organ dysfunction (Ranieri et al., 2012). PSI
[25] and CURB65 [26] are validated scores for mortality
prediction (Shah BA et al., 2010) [27, 28] due to CAP
and were used as described. The PSI score is calculated
from the following parameters; age, sex, nursing home
resident, neoplastic disease, liver disease history, CHF
history, cerebrovascular disease history, renal disease
history, altered mental status, respiratory rate ≥ 30
breaths/min, systolic blood pressure < 90mmhg,
temperature < 35 C or > 39.9 C, pulse ≥125 beats/min,
pH < 7.35, Blood urea ≥30 mg/dL or ≥ 11mmol/L, So-
dium < 130mmol/L, glucose ≥14 mmol/L, hematocrit <
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30%, partial pressure of oxygen < 60 mm Hg and pleural
effusion on Xray. PSI scores of 1 to 3 are classified as
low risk, while PSI 4 to 5 are either moderate or high
risk. CURB65 is derived from the following: Confusion,
blood urea > 7 mmol/l, respiratory rate ≥ 30, systolic
blood pressure < 90 mm Hg diastolic blood pressure
≤ 60 mm Hg and Age ≥ 65 years. CURB65 scores of 0 to
2 are considered low risk; 3 is deemed to be moderate
risk, and 4 to 5 are regarded as high risk.
The WHO definition for severe acute respiratory in-
fection (SARI) was used which includes a history of fever
or measured fever of ≥38 C° with onset in the last 10
days, cough and a requirement for hospitalization [29].
Microbiological workup
After informed consent was obtained, nasopharyngeal
swabs were collected by a trained clinician using Sterile
Snappable Polystyrene & Viscose Amies Swabs (Deltalab,
Barcelona, Spain). Bronchoalveolar lavage (BAL) specimens
were used when available. Samples were stored at − 80 °C
until testing. Nucleic acid extraction was done using
QIAamp Viral RNA Minikit (Qiagen, Germany) as per
manufacturer’s instructions and reverse transcriptase-PCR
was done in a Rotor-gene Q thermal cycler (Qiagen,
Germany) using the FTD Respiratory pathogens 21 test
(Resp21; Fast Track Diagnostics, Luxembourg). Resp21 de-
tects the following pathogens: influenza A virus (unknown
subtype); influenza A(H1N1) virus (swine-lineage); influ-
enza B virus; human rhinovirus; human coronaviruses
NL63, 229E, OC43 and HKU1; human parainfluenza vi-
ruses 1, 2, 3 and 4; human metapneumoviruses A/B; human
bocavirus; human respiratory syncytial viruses A/B; human
adenovirus; enterovirus; human parechovirus and Myco-
plasma pneumoniae. The first 73 patients were tested using
the Resp21 test. The same reagents were not available for
the last four patients, so their samples were tested for Influ-
enza A, H1N1, Influenza B, RSV A and RSV B using Real-
star Influenza Screen & Type RT-PCR Kit 4.0 and Realstar
RSV RT-PCR Kit 3.0 respectively (both produced by Altona
Diagnostics, Hamburg, Germany).
Other microbiological evaluations were performed as
requested by the treating physician and were not influ-
enced by the study personnel. Microbiological reports
that were considered include sputum Gram stains and
cultures and blood cultures as well as influenza or RSV
rapid antigens. Pneumocystis PCR is highly sensitive but
not highly specific, so patients with positive Pneumocys-
tis PCR were evaluated according to clinical characteris-
tics and cytologic findings.
Results
Demographic profile
A total of 77 patients fitting the inclusion criteria were
enrolled in the study (Fig. 1). The median age was 54.5
(IQR 38–71.5) years and 57% were male. Eighty-three
percent had at least one pre-existing condition, including
cardiovascular disease (43%), followed by lung disease
(22%), diabetes mellitus type II (22%), and HIV (13%)
(Table 1). Almost half the study population (46%) had
used an antibiotic before admission, with the most fre-
quently used being aminopenicillins (amoxicillin-clavula-
nate), macrolides (azithromycin) and cephalosporins
(cefuroxime or ceftriaxone).
Most of the enrolled patients had complaints of cough,
fever, difficult breathing, chest pain, and malaise, all of
which were present in at least half the patients. Seventy-
nine percent fit criteria for severe acute respiratory ill-
ness (SARI).
Etiologies
Seventy-five of the 77 enrolled patients had a nasopha-
ryngeal swab obtained for viral PCR using the Resp21
assay as part of the study protocol for 71 patients, while
four were tested by PCR using the Altona influenza and
RSV tests. Other tests were done as determined by the
admitting physician and included blood cultures (60)
and sputum [30]. Bronchoscopy was done in seven. A
potential etiology was identified in 44 (57%) of the pa-
tients (Table 2).
Viral agents were identified in 37 patients (48%) and
for 33 of these patients, the only pathogen identified was
a virus, while the other four had Mycobacteria tubercu-
losis or a pyogenic bacterium identified. Most of the viral
pathogens were identified from nasopharyngeal swabs,
but three of four oropharyngeal swabs and two of the
three BAL samples subjected to PCR had viruses identi-
fied. For the other four patients with BAL performed,
PCR was not performed on the BAL fluid, but was done
on nasopharyngeal swabs obtained upon enrollment and
one had a virus identified.
The most commonly identified virus that is consist-
ently recognized as a lower respiratory pathogen was In-
fluenza A, which was found in 18 patients. It was the
sole pathogen in 11 patients. It was found with one or
more other viruses in three patients, and with bacterial
infection in one patient who had pneumococcal
bacteremia. Diabetes mellitus was the most common co-
morbid condition among patients with Influenza A (9 of
18; 50%) and was found more commonly in those with
influenza than in those without (14 of 57; OR 3.07, 95%
CI 1.02–9.25, p = 0.046). Seven of the patients with influ-
enza identified by PCR also had Influenza rapid antigen
testing done with only two of these positive, indicating
poor performance of the rapid antigen test.
Rhinoviruses were found in 18 patients, but in all but
four, were found with other viruses. For the four patients
with rhinovirus as the only potential pathogen, we in-
cluded it as a cause of pneumonia while recognizing its
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role in LRI as being controversial. Other viruses that were
found included adenovirus, enteroviruses, parainfluenza,
RSV, parechovirus and human metapneumovirus. These
viruses were frequently found in combination. It is notable
that the two patients with adenovirus as the sole agent
presented with temperatures above 40 °C. Viruses were
isolated from patients throughout the 10months of the re-
cruitment period for total viruses (Fig. 2a) and for influ-
enza, specifically (Fig. 2b).
Pyogenic bacteria were identified as pulmonary patho-
gens in seven patients; four with positive blood cultures
and three with potential pathogens from sputum speci-
mens (Table 2). In addition, two of the patients had
positive AFB smears followed by positive cultures for M.
tuberculosis complex.
Of the 10 patients with HIV, three patients had
Pneumocystis pneumonia (PCP). These patients had
CD4 counts of 4, 22 and 340 cells/mm3. One of the pa-
tients with PCP had coinfection with both rhinovirus
and parainfluenza virus 4. The seven HIV positive pa-
tients without PCP included two with influenza, one
with rhinovirus-Klebsiella co-infection and another with
bacteremic pneumococcal pneumonia. No pathogen was
identified among three patients within this cohort and
neither of the two patients with TB presenting as CAP
was HIV-infected.
Fig. 1 Flow chart of patient recruitment
Nambafu et al. BMC Infectious Diseases          (2021) 21:703 Page 4 of 9
Outcomes
In this study, a low risk PSI score of 1–3 was recorded
in 73% of the patients. In the current study, 40% of the
patients had a CURB65 score of 0 and none had the high
risk scores of 4 to 5 despite the number of patients over
65 years (which adds one point to the score). Despite the
low PSI and CURB65 scores, a significant number of pa-
tients (34; 43.6%) patients had at least one complication
(Table 3). The most common was acute kidney injury
(31%), which was found alone in 22% and in combin-
ation with ARDS and/or sepsis in another 9%. In
addition, 30% percent of the admissions were to critical
care units. The average length of hospitalization was 7.4
days, though those in intensive care units spent a mean
of 8 days. Two (3%) of the study patients died within 30
days, seven (9%) had readmission within the same
period.
The morbidity associated with influenza was greater
than that for other viruses or nonviral pneumonia as de-
termined by the number of patients requiring critical
care treatment. Patients with influenza were more likely
to require critical care than those with other viral pneu-
monias (61%; OR 5.32, 95% CI 1.72–16.49, p = 0.004). In
contrast, 21% of those with other viruses not including
influenza and 22% of those with no virus identified re-
quired critical care.
Characteristics of the patients that died within 30 days
Two patients died within 30 days of enrollment, both of
whom had viral pneumonias. One was a 46 year-old fe-
male with diabetes mellitus and hypertension with Influ-
enza A and adenovirus complicated by severe ARDS
who died from respiratory failure. The other patient was
a 59 year-old female with diabetes mellitus and multiple
myeloma. She had parainfluenza pneumonia and was
Table 1 Patient characteristics
Patient Category No. (%) of patients N = 77/ (%)
Age (Mean, SD) 54.0 (±16) Signs
60 years old or more 33 (42.9) RR≥ 30/min 6 (7.8)
Gender Heart rate≥ 125/min 13 (16.9)
Male 44 (57.1) Temperature≥ 39.5 or≤ 35 13 (16.9)
Comorbidities SpO2≤ 92 38 (50.6)
CVD 32 (41.6) SBP < 90 mmHg 8 (10.4)
Diabetes 23 (29.9) Laboratory findings
Lung disorders 26 (33.8) WBC≥ 10,000 34 (44.2)
CKD 9 (11.7) Hemoglobin ≤10 g/dl 6 (7.8)
HIV infection 10 (13.0) Platelets< 150,000 17 (22.1)
Prior Antibiotics 35 (45.5) BUN (Urea) > 7 mmol/l 16 (20.8)
Lifestyle Serum sodium ≤130 10 (13.0)
Active Smoker 5 (6.5) Imaging findings
Alcohol 17 (22.1) Ground glass opacities 27 (35.1)
Other Opacities 14 (18.2)
Symptoms Multiple findingsa 10 (13.0)
SARI 61 (79.2) Consolidations 23 (29.9)
Fever 75 (97.4) Effusions 2 (2.6)
SOB (dyspnea) 60 (77.9) Cavity 1 (1.3)
Chest pain 62 (80.5) Bilateral findingsb 27 (35.1)
Malaise & fatigue 39 (50.6) Case admissions
Sputum 18 (23.4) Non-Critical 53 (68.9)
Weight loss 21 (27.3) Critical Care 20 (26.0)
Wheezing 18 (23.4) Critical Care and Intubated 4 (5.2)
CKD chronic kidney disease
CVD cardiovascular disease (hypertension, arrhythmias and heart failure)
SOB Shortness of breath
SARI Severe Acute Respiratory Illness; defined as a history of fever or
documented temperature of 38 °C and above and cough requiring
hospitalization within the last 10 days
aMultiple findings included reticulonodular changes and peribronchial cuffing
that could not be placed into any of the above categories
bMajority of the bilateral findings were opacities (13/27, 48%)
Table 2 Etiologic agents of pneumonia
Type of infection and agents identified n = 77 (%)
None 33 (42.9)
Viral pathogen alone (single agent) 22 (28.6)
Viral pathogen alone (multiple agents) 11 (14.3)
Bacterial pathogen alone 4 (5.2)
Viral-bacterial co-infection 4 (5.2)
P. jirovecii 3 (3.9)
Viral agents:





Respiratory Syncytial Virus 2 (2.6)
Parechovirus 2 (2.6)
Human Metapneumovirus 1 (1.3)
Bacterial agents:
Blood culture (n = 60)
E. coli 1 (1.3)
S. Typhi 1 (1.3)
S. pneumoniae 2 (2.6)
Bronchial wash culture (n = 7)
M. tuberculosis 1 (1.3)
K. pneumoniae 1 (1.3)
Sputum (n = 39)
M. tuberculosis 1 (1.3)
S. pneumoniae 1 (1.3)
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managed on the non-critical ward and discharged after 7
days of hospitalization. She died 1 day after discharge.
Discussion
This study is one of the few prospective studies of CAP
in adults in SSA. Our study focused on routine viral test-
ing accompanied by testing for other pathogens as or-
dered by the treating physicians. With this combination
of testing, a least one potential pathogen was identified
in 57% of the study population including viruses in 48%,
pyogenic bacteria in 9%, PCP in 5% and TB in 3%. The
percentages add up to more than 57% because of the pa-
tients with coinfections. Influenza A was the most com-
mon pathogen identified in this study, found in 18
patients (24% of total); in 10 as the only pathogen identi-
fied and eight in combination with bacteria or other vi-
ruses. The original aim of the study was to recruit
patients for a full year to allow a more accurate
Fig. 2 Viruses identified; the number on the left indicates the number of cases. A Virus isolation by month; May 2019 to March 2020. B Influenza
by month
Table 3 Pneumonia severity indices and level of care,
complications and outcome
Level of care Total PSI CURB65
1 2 3 4 5 0 1 2 3 4/5
Ward 53 11 24 6 11 1 25 19 7 2 0
Critical care 20 1 7 4 3 4 6 6 5 2 0
Critical + vent 4 0 1 2 1 0 0 2 1 1 0
Complications
AKI 22 2 7 3 6 4 4 6 8 4 0
AKI with RF 2 0 0 1 0 1 0 1 1 0 0
RF 4 0 3 0 1 0 2 1 1 0 0
Outcome at 30 days
Mortality 2 0 1 1 0 0 1 1 0 0 0
Readmission 7 0 1 1 3 2 1 1 4 1 0
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assessment of seasonality; however, when the first
COVID-19 case was identified in Kenya in mid-March,
recruitment was halted at 10 months, limiting our con-
clusions about seasonality. However, cases occurred
throughout the 10 months of observation with no clear
seasonal trend and this finding compares with CDC Sur-
veillance data from Kenya between 2007 to 2013 [31].
Other studies have reported variable trends including
May–July peaks in South Africa [12] and January–Febru-
ary peaks in Kenya [9]. The predominance of H1N1
(72%) in our study contrasts with the predominance of
H3N2 in the northern hemisphere (Radin et al., 2012),
but is consistent with data from east Africa demonstrat-
ing seasonal and year to year variability in the prevalence
of H1N1 [32, 33].
Previous retrospective and prospective studies on
pneumonia in SSA have focused predominantly on bac-
terial pathogens. A study from Kenya in 2000 reported
S. pneumoniae as the most common pathogen, account-
ing for nearly 50% of cases [34]. In the aforementioned
study, antibody testing was used for viral pathogens
allowing the identification of influenza as the etiologic
agent in 5% of patients. Their study was performed in
public hospital with a high percentage of HIV-infected
patients reported as 52% of 281 participants and half of
the S. pneumoniae cases were in HIV-infected patients.
We note that in the current series, three of the 10 HIV-
infected patients had PCP as causes for their CAP, while
one had pneumococcal bacteremia and none had TB.
Other recent studies have demonstrated a wide range of
pathogens. A study in Malawi with an HIV positive adult
cohort of 94% (48/51) found that 29% bacterial infection,
27% PCP, 22% pulmonary TB and only 6% had viral in-
fections [35]. Another study from Cameroon comparing
only clinical parameters among HIV-negative and posi-
tive adults with pneumonia reported a rate of HIV infec-
tion of 59% (62/106) (Yone et al. 2012). Several other
studies among patients with pneumonia have alluded to
the high prevalence of HIV and very little has been men-
tioned about NCDs [34–38].
As in many studies throughout the world, males were
more common than females [37], Underlying conditions
known to confer increased risk for CAP were identified
in 83% of patients of which the most common were car-
diovascular disease, diabetes and chronic pulmonary dis-
ease. A study done in Nigeria [39], revealed 38.8% of
patients with CAP had at least one NCD. Studies from
high and middle income countries have also shown that
NCDs are common in patients presenting with pneumo-
nia [30, 40, 41] and are linked to increased morbidity
and mortality [42–45]. The high percentage of patients
with NCDs in this study reflect the risk factors of a
growing middle class in Nairobi and may be an indica-
tion of trends relevant to SSA [5–7]. It is likely then, that
in the setting of a low HIV prevalence, NCDs will be-
come the major risk factors for CAP. It is therefore use-
ful to compare results from both high HIV prevalence
settings with those from the current study from a private
hospital that has a lower percentage of HIV patients but
a higher percentage of patients with diabetes and other
chronic noncommunicable diseases.
Rhinovirus was found as frequently as influenza,
though primarily as a co-pathogen. However, there were
four cases in which it was the only agent identified. We
therefore included it in our analysis even as we recog-
nized the controversy around its role as a lower respira-
tory pathogen [46–48]. Numerous other respiratory
viruses were also found, either individually or in com-
bination with other viruses or bacteria. It is notable that
there were no cases of Mycoplasma identified, indicating
that it is not a common cause of hospitalization from
CAP.
A meta-analysis by of 31 studies from throughout the
world among adults with CAP reported that viral re-
spiratory pathogens were identified in a pooled propor-
tion of 24.5% (range 8–56%) [49]. Among the viruses,
influenza was the most frequently reported cause of viral
pneumonia folowed by rhinovirus, RSV and human cor-
onaviruses. Similar findings were reported in a system-
atic review of 27 studies that used PCR for diagnosis of
CAP among adults in Europe where they found an aver-
age rate of 22% with a range of 6–45% [50]. Again, influ-
enza was the most commonly identified virus, followed
by rhinovirus and human coronaviruses. Both reviews
reported a high proportion of viral pneumonia with a
dual bacterial-viral infection rate of 10% and higher
mortality rate among patients with dual infection. The
finding of viral isolates in 48% of patients in the current
study was toward the upper range of the reported
studies.
The low CURB65 and PSI scores in the current study
contrast with the high prevalence of complications on
admission including AKI, respiratory failure or sepsis
(total of 43.6% with at least one of these complications)
and requirement for critical care in 31% of patients. Not-
ably, the two mortalities had low CURB65 and PSI
scores (PSI of 2 and 3 with CURB65 of 0 and 1). These
observations are consistent with other studies that have
shown poor ability of these scores to predict prognosis
in viral pneumonia patients [51].
This study has a few limitations. First, we recognize
that bacterial pathogens in this study were under-
recognized, since bacteriologic workup was not part of
the study protocol and many patients either had no spu-
tum submitted or had received antibiotics before the
sputum was collected. It is also possible that viral etiolo-
gies are over-stated, since viral shedding may occur in
the absence of symptoms with respiratory viruses [47,
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52–54]. However, it is noted that patients with viruses
actually had more severe disease as indicated by the
need for critical care treatment and the fact that both
mortalities were in patients with viruses. Finally, as a sin-
gle center study with a 10month duration, we were un-
able to address seasonality or the presence of rare
pathogens.
Conclusions
In conclusion, this study demonstrated that viral respira-
tory pathogens play a major role in the etiology and se-
verity of community acquired pneumonia. It is possible
that the growth in NCDs such as diabetes and cardiovas-
cular disease in SSA will be accompanied by an increase
in community acquired pneumonias with viral pneumo-
nias constituting an important component, especially in
non-HIV-infected patients.
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